Benefits of Nicotinamide Riboside Upon Cognition and Sleep

What Was Tested

The trial (not phased) is built around NAD+.

It had two arms (groups): Intervention (experimental) and Placebo (placebo comparator).

The registry classes the interventions as dietary supplement.

More on the Plan

Ten percent of adults aged ≥ 65 years and fifty percent of adults ≥ 85 years exhibit cognitive impairment.

Consequently, millions of Americans are at risk for both cognitive impairment, including Alzheimer's Disease and other dementias, and disrupted sleep.

Importantly, sleep disturbances and mild cognitive impairment may appear several years before the development of clinical dementia.

Who Took Part

The registry lists 50 planned participants were the target.

It was open to people of any sex aged from 65 years up to 85 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Sleep Quality. Pittsburgh Sleep Quality Index (PSQI) global score \>5.

The full record lists 1 inclusion and 1 exclusion criteria.

How the Study Was Run

Design: randomized, parallel-group and single-blind.

The participants were allocated by chance, so the NAD+ group and the comparison group should start out alike.

Groups ran in parallel: each of the participants stayed in one arm throughout.

In this single-blind NAD+ study one party knew the assignments and the other did not.

Those kept unaware of assignments: participant.

It started in 2023-04-04 with completion listed for 2027-08-30.

It ran at 3 sites in United States (3).

Its stated primary purpose is supportive care.

What Was Measured

Researchers chose this as the main measure: Sleep Quality Assessment (time frame: Change from baseline to endpoint at 12 weeks).

It also tracked 1 secondary outcome, for example Cognitive function.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of NAD+ in 50 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the NAD+ compound page, all human trials.